The amino-terminal domain containing the ligand binding site of the G protein-coupled metabotropic glutamate receptors (mGluRs) consists of two lobes that close upon agonist binding. In this study, we explored the ligand binding pocket of the Group III mGluR4 receptor subtype using site-directed mutagenesis and radioligand binding. The selection of 16 mutations was guided by a molecular model of mGluR4, which was based on the crystal structure of the mGluR1 receptor. 
The family of eight metabotropic glutamate receptors (mGluRs) 1 has been subdivided into three groups based on sequence homology, signal transduction mechanisms, and pharmacological profiles (1, 2) . The Group III mGluRs, which include mGluR4, -6, -7, and -8, are selectively activated by the agonist L(ϩ)-2-amino-4-phosphonobutyric acid (L-AP4; see Fig.  1 ). With the exception of mGluR6, which is localized postsynaptically in cells of the retina, the other Group III mGluRs show primarily a presynaptic localization (3, 4) , although at some synapses these receptors may also be present postsynaptically. Presynaptic Group III mGluRs act as autoreceptors to inhibit the release of L-glutamate from glutamatergic nerve terminals (4 -6) , and ␥-aminobutyric acid release via glutamate spillover onto GABAergic synapses expressing mGluRs (7) . The ability of agonists at Group III mGluRs to inhibit L-glutamate release appears to underlie the neuroprotective properties of this class of compounds in models of neurotoxicity (8, 9) and epilepsy (10 -14) .
Although the prototypical Group III agonist L-AP4 is a synthetic compound that has not been detected in brain tissue, the close structural analogue, L-serine-O-phosphate (L-SOP; Fig. 1 ) is present in mammalian brain tissue at micromolar concentrations (15, 16) . Based on these studies and the observation that mGluR4 and other Group III mGluRs display selectivity and high affinity for L-SOP, we have proposed that this phosphonated amino acid may be an endogenous neurotransmitter or neuromodulator at synapses expressing Group III mGluRs (17) .
The analysis of truncated mGluRs that contain only the extracellular amino-terminal domain has demonstrated that the glutamate binding site is contained within this domain of the receptor protein (18 -20) . Earlier modeling studies based on structural similarities between mGluRs and a group of bacterial proteins known as periplasmic binding proteins, suggested that the amino-terminal domains of mGluRs possess a bilobed "Venus's flytrap" configuration whereby the ligand binds within a cleft between the two lobes causing a closing of the flytrap (21) . The recent elucidation of the crystal structure of the amino-terminal domain of the mGluR1 (Group I) receptor subtype has confirmed this basic arrangement and provides a much more detailed picture of the binding domain of mGluR1 (22) .
Despite the availability of the information provided by the x-ray structure of mGluR1, the molecular determinants that confer receptor subtype selectivity among the mGluRs are not known. Previous mutagenesis and modeling studies have identified residues embedded in the binding pocket that function as fundamental recognition sites common to all eight receptor subtypes (17, 21, (23) (24) (25) . Examples of this class of residues in mGluR4 include arginine 78, serine 159, and threonine 182. However, in addition to the complement of binding residues that are conserved in all mGluRs, an additional subset of amino acids in the binding pocket must be responsible for the unique pharmacological profiles of each of the three subgroups of mGluRs. The goal of the present study was to identify residues within the binding pocket of Group III receptors that mediate high affinity L-AP4 binding. To accomplish this task, we used a combination of molecular modeling, site-directed mutagenesis, and radioligand binding.
EXPERIMENTAL PROCEDURES

Materials
3 H]L-AP4 (specific activity 49 Ci/mol), and [
3 H]CPPG (specific activity 15.5 Ci/mmol) were purchased from Tocris Cookson Inc. (Bristol, UK).
Molecular Modeling-The three-dimensional structure of the proposed ligand binding domain of the rat mGluR4 receptor was formulated by homology modeling using the experimentally determined structure of the closed form of mGluR1 (22) . The atomic coordinates were obtained from the Protein Data Base (PDB code, 1ewk). The QUANTA program (version 2000, Molecular Simulations Inc.) and the SYBYL program (version 6.7, TRIPOS Corp.) were used to view the model that encompassed the region from methionine 40 to tryptophan 508 of the rat mGluR4 sequence. The sequence alignment used to build the mGluR4 model is shown in Fig. 2 . Backbone atom coordinates were assigned the corresponding residue coordinates from the crystal structure of the mGluR1, and side chain atom coordinates were based on maximal side chain atom fitting to the mGluR1 structure using the modeler software from within Quanta. Regions with insertions or deletions were modeled using known substructures identified by loop searching techniques; regions 1-39 and 125-147, which are absent in the mGluR1 structure, were not included in the model. The L-SOP molecule was docked into the binding site of mGluR4 in an orientation corresponding to that observed for glutamate binding to mGluR1. The model was energy-optimized using a restrained energy minimization with additional constraints applied to the backbone regions based on the x-ray structure of the mGluR1 using the CHARMm force field. A steepest descent followed by a conjugate gradient method was used for energy minimization until the energy change per cycle was less than 0.0001 kcal/mol.
Expression Constructs and Site-directed Mutagenesis-The wild-type rat mGluR4a with a c-Myc epitope tag inserted between the amino acids histidine 38 and proline 39 (mGluR4a-cmyc-N) was subcloned into pcDNA3 (Invitrogen) as described previously (19) . The wild-type rat mGluR8a containing a c-Myc-polyhistidine epitope fused to the 3Ј region was subcloned into pcDNA3.1 (Invitrogen) as described previously (20) . An alternative version of the rat mGluR4a with a c-Myc-His epitope fused to the 3Ј end of the mGluR4a cDNA was also produced (termed mGluR4a-cmyc-C). To delete the 3Ј untranslated region of mGluR4a and fuse the c-Myc-His epitope, a PCR was performed on a 3838-bp HindIII-XbaI fragment using the forward primer (5Ј-CCG GGA GCT GAG CTA-3Ј) and the reverse primer (5Ј-TCC CCG CGG GAT GGC ATG GTT GTT-3Ј). The reverse primer deleted the stop codon to allow fusion of the tag and contained a SacII restriction enzyme site. The PCR product was purified and digested with AvrII and SacII, and the 766-bp product was gel-purified. For subcloning into the pcDNA3.1 vector (Invitrogen), full-length mGluR4a cDNA was digested with HindIII and AvrII yielding a 2.1-kb fragment that was gel-purified. The 766-bp AvrII/SacII PCR product and the 2.1-kb HindIII/AvrII mGluR4a fragment were ligated into the HindIII/SacII sites of pcDNA3.1-c-MycHis vector. The resultant mGluR4a-cymc-C was sequenced from the 3Ј end to confirm in-frame fusion of the c-Myc and His tags.
The mGluR8a mutants K71A, K71Y, R75A, and several of the mGluR4a mutants including K74A, K74Y, K74N, K74Q, and H77Q were made using a cassette mutagenesis method. Briefly, the 1.8-kb KpnI fragment of mGluR8a and the 1.8-kb KpnI fragment of mGluR4a were both subcloned into pBluescript SK Ϫ (Stratagene) and transformed into the CJ236 strain of Escherichia coli. Single-stranded DNA was isolated using the Muta-Gene phagemid in vitro mutagenesis kit from Bio-Rad. Mutagenic oligonucleotides were annealed to the singlestranded template and used to make double-stranded mutant DNA. Double-stranded DNA was transformed into DH5␣ E. coli (Invitrogen)-competent cells. Mutated cassettes were then excised from pBluescript SK Ϫ and ligated back into their corresponding vectors. All remaining mutations were made in mGluR4a-cmyc-C and produced by the QuikChange site-directed mutagenesis strategy (Stratagene) according to the manufacturer's instructions using the wild-type mGluR4a 1.8-kb KpnI cassette in pBluescript SK Ϫ as a template. Briefly, two complementary oligonucleotides (31-34 bases) contained the desired base pair changes in the center of the oligos. The mGluR4a cassette was amplified using Pfu Turbo DNA polymerase (Stratagene) for 12-16 cycles in a programmable thermal controller (MJ Research Inc.). Digestion of template (nonmutated) DNA was accomplished with DpnI, and the resultant muted DNA was transformed into DH5␣ E. coli-competent cells. The amplified DNA was digested with transformed into E. coli DH5␣-competent cells. All resultant mutated KpnI cassettes were sequenced via automatic sequencing on a LiCor LongReadIR sequencer prior to subcloning back into the full-length expression vector.
Cell Culture-Transient transfections of human embryonic kidney (HEK) 293-TSA-201 cells were conducted using a calcium phosphate precipitation protocol as described previously (19) . The cells were cultured in modified Eagle's medium with 6% fetal bovine serum and antibiotics. All experiments were conducted on cells or membranes collected 48 h after transfection.
Membrane Preparation and Radioligand Binding Assay-The membrane preparation and the [ 3 H]L-AP4 and [
3 H]CPPG radioligand binding assays were carried out as described previously (26, 27) . Briefly, HEK-293 cells transiently transfected were harvested 48 h post-transfection and pelleted by centrifugation (3,840 ϫ g, 20 min, 4°C). Pelleted cells were suspended in 20 ml of ice-cold lysis buffer (30 mM HEPES, 5 mM MgCl 2 ⅐6H 2 O, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, pH 7.4) and homogenized with a Polytron prior to centrifugation (48,400 ϫ g, 20 min, 4°C). The cell pellets were resuspended in 15 ml of lysis buffer supplemented with 0.08% Triton X-100 and incubated for 10 min at 37°C. Following incubation, an additional 15 ml of lysis buffer was added, and the membranes were recentrifuged at 48,400 ϫ g for 15 min. Cell membranes were washed by resuspension in 15 ml of assay buffer (30 mM HEPES, 110 mM NaCl, 1.2 mM MgCl 2 ⅐6 H 2 O, 5 mM KCl, 2.5 mM CaCl 2 , 0.1 mM phenylmethylsulfonyl fluoride, pH 8.0), centrifuged (48,400 ϫ g, 15 min), and homogenized in 1-5 ml of assay buffer. Protein concentrations were determined using a kit from Bio-Rad. All membranes were diluted in assay buffer to a final concentration of 0.625 mg/ml and stored at Ϫ70°C. For radioligand binding, frozen membranes were thawed and homogenized using a Polytron. 125 g of membrane protein was used for all binding assays in a final volume of 250 l. All assays were performed on ice using either 20 nM [ 37°C for 15 min prior to gel electrophoresis. For immunocytochemical analyses, HEK cells were washed with phosphate-buffered saline (PBS) twice at 48 h post-transfection and fixed with PBS containing 4% paraformaldehyde and 4% sucrose for 10 min at 25°C. The cells were air-dried for 15 min and then incubated in 10% bovine serum albumin in PBS for 30 min at 25°C. The cells were subsequently incubated for 1 h at 25°C with the anti-mGluR4a antibody (Upstate Biotechnology, Inc.) diluted to a final concentration of 0.15 g/ml in 3% bovine serum albumin in PBS. The primary antibody was then removed, and the cells were washed five times for 5 min each with PBS. After washing, the cells were incubated for 60 min at 25°C with biotin-conjugated antimouse IgG (Sigma, B0529) diluted to a final concentration of 2.75 g/ml in 3% bovine serum albumin in PBS. After incubation, the cells were washed five times for 5 min each with PBS and treated with fluorescein isothiocyanate-conjugated ExtrAvidin (Sigma, E-2761) diluted to a final concentration of 5 g/ml in 3% bovine serum albumin in PBS for 60 min at 25°C in the dark; the cells were washed four times for 5 min with phosphate-buffered saline, mounted with 50% glycerol solution in PBS, and photographed with a Zeiss Axiovert 135 TV microscope equipped with a 485-nm excitation and 530-nm emission filter at a magnification of 400ϫ using Kodak Tmax 400 film.
RESULTS
An amino acid sequence alignment of a portion of the aminoterminal domain of the mGluRs is shown in Fig. 2 . The amino acids targeted for mutagenesis are shown in bold; a total of 14 single and 2 double mutants were generated and characterized (Table I ). The rationale for the choice of mutations was based on the homology model of mGluR4 (see below), which was in turn based on the crystal structure of mGluR1. All of the mutants analyzed were made in residues located within the region encompassing the putative glutamate binding pocket cated that several of the mutant receptors were expressed at levels similar to that of wild-type rat mGluR4a (Fig. 3) . Further analysis based on radioligand binding competition experiments defined a class of mutants that were expressed at levels similar to the wild-type mGluR4a and showed no major changes in the affinity for L-AP4. This set of "no substantial effect" mutants included K74A, K74N, K74Q, H77Q, G158A, K317A, and K74A/R258A ( Fig. 3 and Table I ). "No substantial effect" was defined as mutants showing less than a 2-fold change in affinity compared with the wild-type receptor. Another subset of mutants that included D202A, Y230A, R258A, N286A, and D312A displayed expression levels that were slightly to moderately lower than that of the wild-type receptor. The lower level of protein expression seen on immunoblots was reflected in the level of [ 3 H]L-AP4 binding (Fig. 3) . However, this set of mutants also did not show major changes in the IC 50 values compared with the wild-type receptor in autocompetition experiments using radiolabeled and unlabeled L-AP4 (Table I) . The absence of effect of the tyrosine 230 to alanine mutation indicates that a possible cation-pi interaction between the phenyl group of the tyrosine and the amino group of the bound ligand, as suggested for mGluR1 (22) , is not critical for the binding of ligands to Group III mGluRs.
The most interesting class of mutants comprised those that showed levels of protein expression on immunoblots similar to or slightly lower than that of the wild-type receptor but with drastic reductions in the level of [ 3 H]L-AP4 binding. These included K74Y, E287A, K405A, and the K74A/K317A double mutant, which showed 7.6, 4.5, 1.9, and 3.8%, respectively, of wild-type binding (Fig. 3) . Lysine 405, located on lobe I, is conserved in all eight mGluRs. Thus, this amino acid is likely essential for ligand binding to all members of the mGluR family. In contrast, lysine 74 on lobe I and glutamate 287 and lysine 317 on lobe II are not conserved in the mGluR family and therefore are likely not fundamental ligand recognition motifs; these amino acids may contribute to subgroup selective ligand binding. Lysine 74 was mutated to several different amino acids; mutation to the neutral alanine or to glutamine, which mimics mGluR6, or to asparagine, which mimics mGluR7 at this position, did not affect the pharmacological profile (Table  I) . In contrast, mutation of lysine 74 to tyrosine, which mimics mGluR1 at this position, resulted in a great loss of binding (Fig. 3) .
The observations on the series of mutations of lysine 74 in mGluR4 prompted us to confirm these results in the mGluR8 receptor, which is 71% identical to mGluR4 in the aminoterminal domain. Consistent with the results in mGluR4, mutation of lysine 71 to tyrosine in mGluR8 (lysine 71 in mGluR8 is analogous to lysine 74 in mGluR4) induced a sharp decline in the level of [ 3 H]L-AP4 binding (Fig. 4, A and B) . In contrast, mutation of this residue to alanine increased the amount of binding to mGluR8; this was reflected as a nonsignificant increase in the affinity for [ 3 H]L-AP4 (Fig. 4C) . In addition to lysine 71, arginine 75 in mGluR8 was also mutated to alanine; the analogous residues in mGluR1 and mGluR4 (arginine 78, see Table I ) have been shown to be essential for ligand binding to these receptors (17, 23) . As seen with mGluR4, mutation of this critical arginine in mGluR8 virtually eliminated [ 3 H]L-AP4 binding.
The effects of these mutations on the binding of the phosphonophenylglycine antagonist [ 3 H]CPPG to mGluR8 were also investigated. At low nanomolar concentrations, [ 3 H]CPPG can be used as a selective probe for mGluR8 (27) . As observed with [ 3 H]L-AP4 binding, the R75A mGluR8 mutant also showed a large reduction in [ 3 H]CPPG binding (Fig. 4B) . However, in contrast to the absence of any significant change in affinity in [ 3 H]L-AP4 binding to the K71A mGluR8 mutant, the affinity of [ 3 H]CPPG for K71A was ϳ4-fold lower than for the wild-type receptor (Fig. 4C) . The lack of effect on [
3 H]L-AP4 binding combined with the 4-fold reduction in affinity of the mGluR8 K71A for [ 3 H]CPPG, suggests the possibility that the longer length of the CPPG molecule compared with L-AP4 may place the terminal phosphonate group of CPPG in a better position for making an interaction with the side chain of lysine 71 in mGluR8 as compared with the analogous lysine 74 in mGluR4.
The only single point mutation on lobe II that caused a (Fig. 3) . This finding suggests the possibility that K74 could substitute for K317 (or vice versa) in the binding of
The large reductions in binding observed in the K74Y, E287A, K405A, and K74A/K317A mGluR4 mutants could conceivably be because of mutation-induced global protein misfolding. Misfolded plasma membrane proteins are often (but not always) retained within cells rather than trafficked to the cell membrane. 
displayed large reductions in type [
3 H]L-AP4 binding. In cells expressing the wild-type mGluR4 receptor, a clear rim of labeling was seen on the plasma membrane (Fig. 5) . The cellular pattern and distribution of immunostaining observed in the K74Y (not shown), K74A/K317A, E287A, and K405A mutants were essentially identical to those in the unmutated receptor (Fig. 5) . These findings suggest the absence of mutation-induced global protein misfolding. DISCUSSION A homology model of the amino-terminal domain of mGluR4 was constructed based on the crystal structure of mGluR1. The selective Group III agonist L-SOP was "docked" into the binding pocket of mGluR4 in the same orientation that glutamate exists in the binding pocket of the closed form of mGluR1 (Fig. 6) . Based on this model, a series of mutations was made in the amino acids lining the binding pocket of mGluR4 and tested for their ability to bind the agonist [ 3 H]L-AP4. The mutations were distributed over both lobes I and II. We were particularly interested in amino acids that were oriented toward the phosphonate moiety of the docked L-SOP ligand because of their possible involvement in mediating receptor subtype selective pharmacology.
Based on the sequence alignment, the side chains of six positively charged residues ( (17) and the analogous residues in mGluR1 (arginine 78, serine 165, and threonine 188; Refs. 21 and 23) were "killer mutations" causing a near complete loss of ligand binding. These amino acids are conserved in all mGluRs and therefore represent a fundamental recognition motif for ligand binding to this receptor family. Our present results demonstrate that lysine 405 in mGluR4 also belongs to this class of residues, because mutation to alanine virtually eliminates binding, and lysine 405 is conserved in all mGluRs. In the mGluR4 model, lysine 405 is positioned in close proximity to the phosphonate of the docked L-SOP (Fig. 6) and therefore is likely to form an ion pair with the phosphonate of L-SOP or L-AP4 or with the ␥-carboxylic acid group in the case of glutamate as the bound ligand.
Based on data obtained from the crystallographic structure, it was suggested that several additional nonconserved amino acids located on lobe I may play a role in ligand binding to mGluR1 (22) ; these include tyrosine 74, serine 164 and serine 186 in mGluR1. The analogous amino acids in mGluR4 are lysine 74, glycine 158, and alanine 180, respectively. Although serine 164 in mGluR1 could be important for the binding of ligands to Group I receptors, our data show that the analogous glycine (Gly 158 ) at this position in mGluR4 is not critical for L-AP4 binding to mGluR4. Serine 186 in mGluR1 and alanine 180 in mGluR4 are likely not amenable to analysis via mutagenesis, as the interaction with ligand is mediated by atoms within the backbone of this amino acid (i.e. not with the side chains of serine or alanine; Ref. 22 ). Lysine 74 on lobe I was subjected to a more in-depth analysis because of its close proximity to the docked L-SOP in mGluR4 and because the analogous tyrosine in mGluR1 is involved in binding the Group I ligand [
3 H]quisqualic acid (22) . Mutation of lysine 74 in mGluR4 to alanine (default neutral residue), glutamine (to mimic mGluR6 at this position), or asparagine (to mimic mGluR7) had no significant effect on protein expression or ligand binding affinity. In contrast, mutation to tyrosine to mimic mGluR1 at this position produced a large decrease in [ 3 H]L-AP4 binding; a similar effect was observed with the analogous mutation (K71A) in mGluR8. Together, these mutagenesis data on lysine 74 suggest that the decrease in binding to this mutant is caused by steric hindrance in the binding pocket due to the large bulky aromatic side chain of the tyrosine. The tyrosine in the binding pocket of Group I mGluRs may interact with group I ligands, but the presence of tyrosine at this position in Group III receptors could block access of L-AP4 to the binding site.
A sequence alignment of the mGluRs (see Fig. 2 ) shows that at position lysine 74 in mGluR4, this residue is a tyrosine in the Group I receptors mGluR1 and mGluR5, an arginine in the Group II receptors mGluR2 and mGluR3, a lysine in both mGluR4 and mGluR8, a glutamine in mGluR6, and an asparagine in mGluR7. The juxtaposition of this residue in close proximity to the bound or docked ligand as determined by the crystal structure of mGluR1, and in the present molecular model of mGluR4, indicates that this amino acid could be a useful molecular handle for structure-based design of novel mGluR compounds.
Like lysine 74, glutamate 287 and lysine 317 in mGluR4 are not conserved in the mGluR family. At the position equivalent to glutamate 287 in mGluR4, a glutamate is also present in mGluR6 and mGluR8, an aspartate occupies this position in mGluR7, a glycine exists in the Group I receptors (mGluR1 and mGluR5), and a serine is present in this position in the Group II mGluRs (mGluR2 and mGluR3). The alignment shows that lysine 317 is conserved in the Group III receptors, whereas the Group I receptors have an arginine, mGluR2 has a leucine, and mGluR3 has a glutamine at this position. The model of the binding pocket of mGluR4 indicates that the side chains of lysine 74, glutamate 287, and lysine 317 are very close to the phosphonate group of the docked L-SOP ligand. Therefore it might be expected that the positive charge imparted by the side chain of lysine 317 could make an ionic bond with the negative charge of the phosphonate group of the L-SOP. Surprisingly however, the K317A mutation showed a wild-type pharmacological profile, whereas the E287A mutant displayed a drastic loss of [ 3 H]L-AP4 binding. A similar loss of binding was seen in the K74A/ K317A double mutant but not in the K74A/R258A double mutant.
These observations, together with the molecular model and the mutagenesis results showing that none of the K74A, R258A, and K317A single mutants displayed changes in their pharmacological profiles, lead us to postulate the following interactions in this potentially important region of the binding pocket of Group III mGluRs.
The mGluR4 model indicates that the amino groups on the side chains of lysines 74 and 317 are 2.6 and 2.7 angstroms, respectively, from the oxygen atoms on the phosphonate group of L-SOP. The phosphonate group of L-SOP could make ion pair bonds with either lysine 74 or 317 or with both residues. In the absence of one of these positive charges, the other positive charge can substitute, but if both are removed the energy is too low to retain a measurable level of binding. The loss of agonist binding upon mutation of glutamate 287 is consistent with the molecular model showing that the side chain of this residue also projects toward the phosphonate of the L-SOP. Glutamate 287 in mGluR4 aligns with glycine 293 in mGluR1. In the crystal structure of mGluR1, the backbone of glycine 293 donates a hydrogen bond to a water molecule, which mediates the interaction between the backbone of glycine 293 and the side chain carboxylic acid group of the bound glutamate ligand. The negative charge on the side chain of glutamate 287 in mGluR4 is unlikely to make a direct contact with the negatively charged phosphonate functional group on L-SOP. We suggest that glutamate 287 may interact with the positively charged side chains of lysines 74 and/or 317 so as to orient them in the correct position for optimizing the bonds between the two lysines and the bound ligand.
In conclusion, our results demonstrate that the residues crucial for high affinity agonist binding to mGluR4 are distributed across both lobes I and II. The data also reveal important differences for the molecular basis of ligand binding between Groups I and III mGluRs that may have implications for the design of highly selective mGluR ligands. In light of the rapidly expanding potential therapeutic applications of mGluR ligands (29 -31) , it will be imperative in future structure/function studies to ascertain the complete complement of amino acids that mediate the group-and subtype-specific binding of ligands to the mGluR family.
